A detailed history of Erste Asset Management Gmb H transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 31,400 shares of ALLO stock, worth $64,684. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,400
Holding current value
$64,684
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $65,312 - $109,900
31,400 New
31,400 $91.4 Million
Q1 2022

Nov 22, 2024

SELL
$7.65 - $15.29 $71,910 - $143,726
-9,400 Reduced 23.04%
31,400 $294 Million
Q4 2021

Nov 22, 2024

BUY
$13.13 - $24.52 $123,422 - $230,488
9,400 Added 29.94%
40,800 $626 Million
Q3 2020

Nov 22, 2024

BUY
$32.38 - $44.96 $304,372 - $422,624
9,400 Added 29.94%
40,800 $1.54 Billion
Q1 2020

Nov 22, 2024

BUY
$18.22 - $28.25 $171,268 - $265,550
9,400 Added 29.94%
40,800 $819 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $296M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.